All Updates

All Updates

icon
Filter
Partnerships
Myriad Genetics and MD Anderson partner to use minimal residual disease platform
Precision Medicine
Jun 12, 2023
This week:
M&A
N-able acquires Adlumin for USD 266 million to strengthen cybersecurity offerings
Next-gen Cybersecurity
Today
M&A
Bitsight acquires Cybersixgill for USD 115 million to enhance threat intelligence capabilities
Cyber Insurance
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Generative AI Infrastructure
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Data Infrastructure & Analytics
Today
M&A
Almanac acquires Gro Intelligence's IP assets for undisclosed sum
Smart Farming
Yesterday
Partnerships
Aduro Clean Technologies partners with Zeton to build hydrochemolytic pilot plant
Waste Recovery & Management Tech
Yesterday
Funding
Oishii raises USD 16 million in Series B funding from Resilience Reserve
Vertical Farming
Yesterday
Management news
GrowUp Farms appoints Mike Hedges as CEO
Vertical Farming
Yesterday
M&A
Rise Up acquires Yunoo and expands LMS monetization capabilities
EdTech: Corporate Learning
Yesterday
Product updates
Uber releases five new features for holiday travel season
Travel Tech
Yesterday
Precision Medicine

Precision Medicine

Jun 12, 2023

Myriad Genetics and MD Anderson partner to use minimal residual disease platform

Partnerships

  • Molecular diagnostic company Myriad Genetics has partnered with The University of Texas MD Anderson Cancer Center to conduct research focusing on treatment selection and response for metastatic renal cell carcinoma (RCC).

  • The collaboration will utilize Myriad's minimal residual disease (MRD) testing platform, designed to detect circulating tumor DNA (ctDNA) in individuals with metastatic RCC and other cancers. The MRD testing system utilizes whole-genome sequencing, enabling the identification and tracking of thousands of variants present in the tumor, resulting in a tumor-informed, high-definition assay.

  • The research project aims to explore the potential of Myriad's MRD testing platform as a non-invasive tool for guiding treatment selection, monitoring disease progression, and assessing radiotherapy treatment response in individuals with metastatic RCC. 

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.